A detailed history of Hudson Bay Capital Management LP transactions in Bio N Tech Se stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 130,000 shares of BNTX stock, worth $15.9 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
130,000
Previous 346,600 62.49%
Holding current value
$15.9 Million
Previous $27.9 Million 44.56%
% of portfolio
0.07%
Previous 0.15%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$78.36 - $124.66 $17 Million - $27 Million
-216,600 Reduced 62.49%
130,000 $15.4 Million
Q2 2024

Aug 14, 2024

BUY
$80.36 - $102.87 $14.2 Million - $18.2 Million
176,600 Added 103.88%
346,600 $27.9 Million
Q1 2024

May 15, 2024

BUY
$88.96 - $112.35 $7.12 Million - $8.99 Million
80,000 Added 88.89%
170,000 $15.7 Million
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $3.18 Million - $3.95 Million
35,000 Added 63.64%
90,000 $9.5 Million
Q3 2023

Nov 14, 2023

SELL
$98.5 - $125.08 $2.46 Million - $3.13 Million
-25,000 Reduced 31.25%
55,000 $5.98 Million
Q2 2023

Aug 14, 2023

BUY
$102.58 - $129.66 $4.1 Million - $5.19 Million
40,000 Added 100.0%
80,000 $8.63 Million
Q1 2023

May 15, 2023

BUY
$122.57 - $153.67 $4.9 Million - $6.15 Million
40,000 New
40,000 $4.98 Million
Q3 2022

Nov 14, 2022

BUY
$127.65 - $183.11 $319,125 - $457,775
2,500 Added 33.33%
10,000 $1.35 Million
Q2 2022

Aug 12, 2022

SELL
$123.25 - $186.24 $1.85 Million - $2.79 Million
-15,000 Reduced 66.67%
7,500 $1.12 Million
Q1 2022

May 16, 2022

BUY
$126.25 - $231.85 $2.84 Million - $5.22 Million
22,500 New
22,500 $3.84 Million
Q2 2020

Aug 12, 2020

SELL
$38.58 - $66.74 $771,600 - $1.33 Million
-20,000 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$28.55 - $92.0 $571,000 - $1.84 Million
20,000 New
20,000 $1.17 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $29.6B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.